Warren HuffFounding Chief Executive Officer and President
Warren is the Chairman, Chief Executive Officer and President of Reata Pharmaceuticals. He has served as our sole CEO, President, and as Chairman of the Board of Directors since our founding in 2002. Prior to founding Reata, Warren served as CEO in a number of health care and information technology start-up enterprises. Warren started his career as an attorney with Johnson & Gibbs, P.C., where he was a partner and Chairman of the Corporate Securities Practice. He received a B.B.A. magna cum laude from the University of Texas at Austin and a J.D. from Southern Methodist University Dedman School of Law.
Dawn C. BirChief Commercial Officer
Dawn is Reata’s Chief Commercial Officer and leads marketing, market access, sales, training, and commercial operations. She joined Reata in September 2016. Prior to joining Reata, Dawn served as Vice President of Sales with Pharmacyclics, LLC, where she built and led their first hematology national sales organization of sales representatives, division managers, and regional sales directors, and was responsible for the launch of IMBRUVICA in the United States and Puerto Rico. Before that, Dawn served as Vice President of Sales & Marketing with McKesson US Pharmaceutical, SKY Pharmaceuticals, and RxPak. She held positions of increasing responsibility within McKesson Corporation, Genentech, Inc., and Bristol-Myers Squibb Company. Dawn holds a B.S. in Biology from Binghamton University.
Colin Meyer, M.D.Chief Medical Officer and Vice President, Product Development
Colin is Reata’s Chief Medical Officer and leads product development and strategy, clinical trial design and analysis, and medical affairs. He joined Reata in 2003. Colin received a B.S. in chemistry with specialization in biochemistry and a B.A. in biology from the University of Virginia. He received an M.D. from the University of Texas Southwestern Medical School and an M.B.A. from Southern Methodist University Cox School of Business.
Keith Ward, Ph.D.Chief Development Officer
Keith is Reata’s Chief Development Officer and leads research and development, clinical operations, manufacturing, regulatory affairs, and project management. Keith joined Reata in July 2011. Prior to joining Reata, he developed ophthalmic pharmaceuticals and medical devices as Global Vice President of Pharmaceutical R&D for Bausch & Lomb Incorporated from September 2008 to June 2011. Before that, he held positions of increasing responsibility within GlaxoSmithKline PLC and SmithKline Beecham Pharmaceuticals. He earned a B.S. in Toxicology with a minor in Chemistry from Northeast Louisiana University and a Ph.D. in Toxicology from The University of North Carolina at Chapel Hill.
Jason WilsonChief Financial Officer and Vice President, Strategy
Jason is Reata’s Chief Financial Officer and leads corporate strategy, finance, accounting and treasury, human resources, business development, investor relations, and information technology. He joined Reata in 2006. Jason is a member of the Board of Directors of CytoSen Therapeutics. Prior to joining Reata he held positions as Vice President, Finance & Corporate Controller at Caris Diagnostics and as a Senior Manager in the health-sciences group at Ernst & Young LLP. He holds a B.B.A. in Accounting from Henderson University and an M.B.A. from University of Central Arkansas.
Michael D. WortleyChief Legal Officer
Mike joined Reata as Chief Legal Officer and Vice President in April 2015. Prior to joining Reata, Mike was an attorney at Vinson & Elkins LLP, serving in various capacities, including Chief Operating Partner of the firm and Managing Partner of the Dallas office, and at Johnson & Wortley, P.C., serving as Chairman of the Board and President. He currently serves on the board of directors of Pioneer Natural Resources Company. He earned a B.A. in Political Science from Southern Methodist University, a Master’s degree in Regional Planning from the University of North Carolina at Chapel Hill, and a J.D. from Southern Methodist University Dedman School of Law.
Elaine CastellanosVice President, Finance & Accounting
Elaine is Reata’s Vice President of Finance and Accounting and oversees financial planning, budget management, and financial accounting and reporting, including ensuring company accounting procedures and reporting conform to generally accepted accounting principles. She joined Reata in 2008 and has over 20 years of financial accounting and reporting experience. She was previously a Senior Manager in the health sciences group at Ernst & Young, with clients ranging from non-profits and development stage companies to the Fortune 500. Elaine received a B.A. in Economics and Managerial Studies and a Masters of Accounting from Rice University. She is also a Certified Public Accountant.
David ChapmanVice President, Marketing
David is Reata’s Vice President of Marketing. He joined Reata in March 2017 with over 25 years of pharmaceutical market experience and leads marketing activities across the product portfolio. Prior to joining Reata, David held positions of increasing responsibility in Global Marketing, Managed Markets, and Sales. He began his career at Pfizer and also worked at Boehringer Ingelheim Pharmaceuticals and Relypsa Pharmaceuticals. David holds a B.S. in Management from Auburn University.
Arthur Gibson, IIIVice President, Bioinformatics
Arthur is Reata’s Vice President of Bioinformatics. He joined Reata in 2010 and oversees data management, database programming, reporting and analysis, and corporate risk management functions. Prior to joining Reata, he held positions of increasing responsibility in data management and clinical programming for CRO’s, biotechnology and pharmaceutical companies, including PPD, ILEX Oncology, Baxter Healthcare, and Encysive Pharmaceuticals. Arthur received a B.S. in Health Administration and an M.S. in Health Research from Texas State University.
Vineet JindalVice President, Strategy
Vineet is Reata’s Vice President of Strategy and oversees corporate strategy, investor relations, and corporate communications. Prior to joining Reata, Vineet was the CEO of QuikFlo Health, a publicly-traded healthcare company, and the co-founder and CEO of Stockr Inc., a social media platform for stock market investors. Previously, Vineet was a Managing Director and the Head of Healthcare Equity Research at ThinkEquity Partners, and was a Vice President of Biotechnology Equity Research at Wedbush Securities. He holds a B.A. in Integrative Biology and an M.A. in Endocrinology from U.C. Berkeley, and an M.S. in Pharmacology from Cornell University.
Robin KralVice President, Licensing & Intellectual Property
Robin is Reata’s Vice President of Licensing and Intellectual Property. He joined Reata in 2004 from the University of Texas Southwestern Medical Center at Dallas, where as Associate Director for Venture Development, he played a leading role in assembling Reata’s extensive project portfolio and initial business plan. Before joining the University of Texas Southwestern, he was in positions of increasing responsibility in research, market and competitive analysis, product development, and business development at NPS Pharmaceuticals in Salt Lake City. Robin has B.S. and M.S. degrees in biology from Texas Tech University, and received his M.B.A. from the David Eccles School of Business at the University of Utah.
Joel Proksch, Ph.D.Vice President, Regulatory & Development
Joel is Reata’s Vice President of Regulatory and Development. He joined Reata in 2012 and oversees the regulatory affairs, pharmacovigilance, and preclinical development functions. Prior to joining Reata, he held positions of increasing responsibility in preclinical development and clinical pharmacology for several biotechnology and pharmaceutical companies, including Bausch & Lomb, 3M Pharmaceuticals, Molecumetics, and SmithKline Beecham Pharmaceuticals. Joel received a B.S. in Chemistry from Hamline University and a Ph.D. in Pharmacology from the University of Arkansas for Medical Sciences.
Robert (Bob) Reed, Ph.DVice President, CMC
Bob is Reata’s Vice President of CMC. He joined Reata in 2018 with over 28 years of experience in drug development and oversees the development and characterization for drug substance and drug product and product supply for all development programs. Prior to joining Reata, he held positions of increasing responsibility in pharmaceutical research & development, pharmaceutical operations, regulatory CMC, Quality and supply operations for several biotechnology and pharmaceutical companies, including The Liposome Company, Merck and Company, Inc., XenoPort Corporation, Celsion Corporation, and Aradigm Corporation. Bob received a B.S. in Chemistry from Eastern Nazarene College, a Ph.D. in Analytical Chemistry from the University of North Carolina at Chapel Hill and spent three years as an NIH Postdoctoral Fellow at Princeton University. Bob has been recognized as an American Association of Pharmaceutical Scientists (AAPS) Fellow.
Mike Visnick, Ph.D.Vice President, Discovery Chemistry
Mike is Reata’s Vice President of Discovery Chemistry. He joined Reata in 2007 with over 25 years of experience in drug discovery while with multiple firms including Hoffmann LaRoche, Parke-Davis, and Pfizer. Prior to joining Reata, Mike has managed research groups in the inflammatory, metabolic and CNS disease areas, as well as directed the computational sciences group at Pfizer in Ann Arbor, Michigan. Mike received his Ph.D. in organic chemistry from the University of Florida and spent two years as an American Cancer Society Postdoctoral Fellow at the University of Pennsylvania. He is an Adjunct Professor of Chemistry at the University of Michigan College of Pharmacy in Ann Arbor, Michigan.
W. Christian Wigley, Ph.D.Vice President, Research & Founding Scientist
Chris is Reata’s Vice President of Research and Founding Scientist and oversees high throughput screening (HTS), discovery biology, and in vitro pharmacology activities. He joined Reata in 2003 and was co-inventor of Reata’s protein folding corrector discovery platform. With over 24 years’ experience, Chris is recognized as a leader in the field of protein misfolding and disease. Prior to joining Reata, he was a Senior Research Scientist in the Department of Physiology at the University of Texas Southwestern Medical Center. Chris received a B.S. in Biochemistry and a Ph.D. in Chemistry from Texas Tech University. His post-doctoral training was conducted in the Departments of Molecular Genetics and Physiology at the University of Texas Southwestern Medical Center.